Investigational drug · Phase 3
Milvexian
Also called: JNJ-70033093, BMS-986177
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
26
Any phase or sponsor naming "Milvexian"
First trial start
2023
Feb 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Milvexian", any sponsor or status.
- Phase 121
Conditions studied
As listed on its trial records.
- Ischemic Stroke; Ischemic Attack, Transient
- Atrial Fibrillation
- Acute Coronary Syndrome
Approved drugs for the same conditions: Atrial fibrillation · Stroke prevention · Coronary artery disease and heart attack · Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Milvexian" as an intervention, largest first.
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05757869 · 20,284 participants · Start Apr 11, 2023 · Primary completion Dec 8, 2026
Drug: Milvexian; Apixaban and 2 more · For: Atrial Fibrillation
Sites: Alexander City, Alabama; Birmingham, Alabama; Dothan, Alabama · 1,052 sites in all
- A Study of Milvexian in Participants After a Recent Acute Coronary SyndromePivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05754957 · 14,194 participants · Start Apr 7, 2023 · Primary completion Feb 6, 2026
Drug: Milvexian · For: Acute Coronary Syndrome
Sites: Alexander City, Alabama; Birmingham, Alabama; Mobile, Alabama · 1,003 sites in all
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05702034 · 12,523 participants · Start Feb 15, 2023 · Primary completion Oct 15, 2026
Drug: Milvexian; Placebo · For: Ischemic Stroke; Ischemic Attack, Transient
Sites: Mesa, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 880 sites in all
- A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03766581 · 2,366 participants · Start Jan 27, 2019 · Primary completion Mar 31, 2022
Drug: BMS-986177; Clopidogrel and 1 more · For: Acute Ischemic Stroke; Transient Ischemic Attack (TIA)
Sites: Birmingham, Alabama; Glendale, California; Long Beach, California · 424 sites in all
- A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement SurgeryPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03891524 · 1,242 participants · Start Jun 17, 2019 · Primary completion Apr 6, 2021
Drug: JNJ-70033093 25 mg; JNJ-70033093 50 mg and 4 more · For: Arthroplasty, Replacement, Knee
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 117 sites in all
- A Study of JNJ-70033093 (Milvexian) in Healthy Adult ParticipantsPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04844424 · 115 participants · Start Apr 14, 2021 · Primary completion May 6, 2022
Drug: Milvexian · For: Healthy
Sites: Salt Lake City, Utah
- A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy SubjectsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03698513 · 113 participants · Start Oct 4, 2018 · Primary completion Feb 19, 2019
Drug: BMS-986177; Clopidogrel and 1 more · For: Healthy Volunteers
Sites: Austin, Texas
- Safety and Tolerability Study of BMS-986177 in Healthy SubjectsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02608970 · 104 participants · Start Dec 31, 2015 · Primary completion Jul 23, 2017
Drug: BMS-986177 · For: Thrombosis
Sites: Antwerp, Belgium
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04223349 · 66 participants · Start Jan 10, 2020 · Primary completion Apr 8, 2020
Drug: JNJ-70033093; Placebo · For: Healthy
Sites: Salt Lake City, Utah
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04543383 · 52 participants · Start Jul 27, 2020 · Primary completion Jun 7, 2023
Drug: Milvexian; 4-Factor Prothrombin Complex Concentrate (4F-PCC) and 3 more · For: Healthy
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- One class, different indications: Factor XIa inhibition after LIBREXIA-ACS.
Palaiodimou L, Tsivgoulis G · Med 2026
- Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro.
Guo X, Fredenburgh JC, Weitz JI · J Thromb Haemost 2026
- Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.
Kidder E, Dhanesha N · Curr Opin Hematol 2026
- FXIa inhibitors and secondary stroke prevention.
Palaiodimou L, Theodorou A, Stefanou MI, et al. · Curr Opin Neurol 2026
- Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
Gibson CM, Steg PG, Bahit MC, et al. · N Engl J Med 2026
- Identification of Plasma Protein Biomarkers for Early-Onset Stroke through Mendelian Randomization.
Huynh AL, Gaynor BJ, Cole JW, et al. · medRxiv 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.